ArticleJournal of controlled release : official journal of the Controlled Release Society2025
Nanoceria as a non-steroidal anti-inflammatory drug for endometriosis theranostics.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Dual-Targeted Nanotherapy Restores Redox Homeostasis and Suppresses Uterine Hypercontractility for Effective Preterm Birth Intervention.Advanced healthcare materials · 2026Article
- Photoacoustic Imaging for Women's Gynecological Health: Advances and Clinical Prospects.Bioengineering (Basel, Switzerland) · 2026Review
- YWHAZ loss is associated with endometrial dysfunction in proliferative-phase endometriosis.Reproduction (Cambridge, England) · 2026Article
- Dietary Caloric Restriction Suppresses Endometriosis by Inhibiting STAT3/ERK Pathways.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Biological Applications of Functionalized Cerium Oxide Nanoparticles.International journal of medical sciences · 2026Review
- Research Advances in the Endometriotic Microenvironment: Synergistic Immune-Inflammatory-Angiogenic Interactions and their Therapeutic Translation.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Nanotechnology strategies for endometrium health: Are we on the right track?Bioactive materials · 2025Review
- ZMIZ1 and estrogen receptor α form an essential partnership in endometrial biology.The Journal of clinical investigation · 2025Article
- Nanoceria as Next-Generation Immunotherapeutics: Applications in Chronic Inflammation, Cancer, and Tissue Repair.Journal of nanotheranostics · 2025Article
- The interplay between endometriosis and obesity.Trends in endocrinology and metabolism: TEM · 2025Review
- Development of a Collagen-Cerium Oxide Nanohydrogel for Wound Healing: In Vitro and In Vivo Evaluation.Biomedicines · 2025Article
- FOXA2 loss results in an increase of endometriosis development and LIF reveals a therapeutic effect for endometriosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Identification and validation of lactate-related gene signatures in endometriosis for clinical evaluation and immune characterization by WGCNA and machine learning.Frontiers in cell and developmental biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Endometriosis, the growth of endometrial-like tissue outside the uterus, causes chronic pain and infertility in 10 % of reproductive-aged women worldwide. Unfortunately, no permanent cure exists, and current medical and surgical treatments offer only temporary relief. Endometriosis is a chronic inflammatory disease characterized by immune system dysfunction. Our previous study showed aberrant activation of signal transducer and activator of transcription 3 (STAT3) in endometriosis. Our transcriptomic analysis of uterine tissue from uterine-specific Stat3 knock-out mice identifies that STAT3 regulates inflammatory and immune-related genes. Here, we evaluate cerium-oxide nanoparticles (nanoceria) as a non-steroidal anti-inflammatory drug for endometriosis theranostics. Our in vitro studies validate the multi-enzymatic properties of nanoceria, enabling the transition of pro-inflammatory macrophages to an anti-inflammatory state in J774 macrophage cells. In vivo, treatment of endometriosis mice with nanoceria reveals its ability to passively accumulate at ectopic lesions. The nanoceria conjugated with indocyanine green are non-invasively trackable to ectopic lesions. Therefore, immune modulation and anti-inflammatory effects of nanoceria significantly reduce development of ectopic lesions while minimizing off-target effects, such as avoiding interference with pregnancy including implantation and decidualization. Our results suggest that aberrant STAT3 activation is a major contributor to endometriosis, and nanoceria offers a novel theranostic approach for endometriosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.